A Bannowsky1, H Schulze, C van der Horst, K-P Jünemann. 1. Klinik für Urologie und Kinderurologie, Universitätsklinikum Schleswig-Holstein,Campus Kiel, Kiel, Deutschland. andreas.bannowsky@klinikum-os.de
Abstract
OBJECTIVE: The purpose of this study was to evaluate the effect of low-dose sildenafil (25 mg) for rehabilitation of erectile function after nerve-sparing radical prostatectomy. PATIENTS AND METHODS: In a prospective study, 43 sexually active patients underwent nerve-sparing retropubic radical prostatectomy. Rigiscan® measurement of nocturnal penile tumescence and rigidity (NPTR) was carried out 7-14 days after surgery. A group of 23 patients with preserved nocturnal erections received sildenafil 25 mg/day at night to support recovery of erectile function. A control group of 18 patients underwent follow-up without PDE-5 inhibitors. Evaluation using the IIEF-5 questionnaire was performed 6, 12, 24, 36, 52 and 78 weeks after the operation. RESULTS: Of 43 patients, 41 (95%) showed 1-5 erections during the first night after catheter removal. In the group receiving daily sildenafil, the mean IIEF-5 score decreased or increased from 20.8 preoperatively to 3.6 at 6 weeks, 3.8 at 12 weeks, 5.9 at 24 weeks, 9.6 at 36 weeks, 14.1 at 52 weeks and 19.3 at 78 weeks after prostatectomy. In the control group, the mean preoperative IIEF-5 score of 21.2 decreased or increased to 2.4 at 6 weeks, 3.8 at 12 weeks, 5.3 at 24 weeks, 6.4 at 36 weeks, 9.3 at 52 weeks and 13.2 at 78 weeks. Statistical evaluation showed significant differences regarding the IIEF-5 score and recovery period of erectile function between the groups (p<0.001), with potency rates of 92 vs 68%. CONCLUSION: The measurement of NPTR after nerve-sparing radical prostatectomy showed erectile function as early as the first night after catheter removal. In cases of early penile erections, daily low-dose PDE-5 inhibitors lead to a significant improvement/acceleration of erectile function recovery.
OBJECTIVE: The purpose of this study was to evaluate the effect of low-dose sildenafil (25 mg) for rehabilitation of erectile function after nerve-sparing radical prostatectomy. PATIENTS AND METHODS: In a prospective study, 43 sexually active patients underwent nerve-sparing retropubic radical prostatectomy. Rigiscan® measurement of nocturnal penile tumescence and rigidity (NPTR) was carried out 7-14 days after surgery. A group of 23 patients with preserved nocturnal erections received sildenafil 25 mg/day at night to support recovery of erectile function. A control group of 18 patients underwent follow-up without PDE-5 inhibitors. Evaluation using the IIEF-5 questionnaire was performed 6, 12, 24, 36, 52 and 78 weeks after the operation. RESULTS: Of 43 patients, 41 (95%) showed 1-5 erections during the first night after catheter removal. In the group receiving daily sildenafil, the mean IIEF-5 score decreased or increased from 20.8 preoperatively to 3.6 at 6 weeks, 3.8 at 12 weeks, 5.9 at 24 weeks, 9.6 at 36 weeks, 14.1 at 52 weeks and 19.3 at 78 weeks after prostatectomy. In the control group, the mean preoperative IIEF-5 score of 21.2 decreased or increased to 2.4 at 6 weeks, 3.8 at 12 weeks, 5.3 at 24 weeks, 6.4 at 36 weeks, 9.3 at 52 weeks and 13.2 at 78 weeks. Statistical evaluation showed significant differences regarding the IIEF-5 score and recovery period of erectile function between the groups (p<0.001), with potency rates of 92 vs 68%. CONCLUSION: The measurement of NPTR after nerve-sparing radical prostatectomy showed erectile function as early as the first night after catheter removal. In cases of early penile erections, daily low-dose PDE-5 inhibitors lead to a significant improvement/acceleration of erectile function recovery.
Authors: A Bannowsky; H Schulze; C van der Horst; J H Stübinger; F J Martinez Portillo; K P Jünemann Journal: Urologe A Date: 2005-05 Impact factor: 0.639
Authors: F Montorsi; G Guazzoni; L F Strambi; L F Da Pozzo; L Nava; L Barbieri; P Rigatti; G Pizzini; A Miani Journal: J Urol Date: 1997-10 Impact factor: 7.450
Authors: F Montorsi; T Maga; L F Strambi; A Salonia; L Barbieri; V Scattoni; G Guazzoni; A Losa; P Rigatti; G Pizzini Journal: Urology Date: 2000-12-20 Impact factor: 2.649
Authors: Andreas Bannowsky; Heiko Schulze; Christof van der Horst; Christoph Seif; Peter Martin Braun; Klaus-Peter Jünemann Journal: J Urol Date: 2006-06 Impact factor: 7.450
Authors: Andrea Salonia; Andrea Gallina; Giuseppe Zanni; Alberto Briganti; Federico Dehò; Antonino Saccà; Nazareno Suardi; Luigi Barbieri; Giorgio Guazzoni; Patrizio Rigatti; Francesco Montorsi Journal: Eur Urol Date: 2007-08-20 Impact factor: 20.096
Authors: Francesco Montorsi; Alberto Briganti; Andrea Salonia; Patrizio Rigatti; Arthur L Burnett Journal: Eur Urol Date: 2004-02 Impact factor: 20.096
Authors: Francesco Montorsi; Gerald Brock; Jay Lee; JoAnn Shapiro; Hendrik Van Poppel; Markus Graefen; Christian Stief Journal: Eur Urol Date: 2008-07-09 Impact factor: 20.096
Authors: Yiannis A Philippou; Jae Hung Jung; Martin J Steggall; Stephen T O'Driscoll; Caitlin J Bakker; Joshua A Bodie; Philipp Dahm Journal: Cochrane Database Syst Rev Date: 2018-10-23